Page 146 - 《中国药房》2025年13期

Resist Updat，2023，68：100951. [38] KIM N H，JEGAL J，KIM Y N，et al. The effects of Aro‐
[27] ERGUL M，BAKAR-ATES F. Investigation of molecular nia melanocarpa extract on testosterone-induced benign
mechanisms underlying the antiproliferative effects of col‐ prostatic hyperplasia in rats，and quantitative analysis of
chicine against PC3 prostate cancer cells[J]. Toxicol In Vi‐ major constituents depending on extract conditions[J]. Nu‐
tro，2021，73：105138. trients，2020，12（6）：1575.
[28] HUSSAIN M，TOMBAL B，SAAD F，et al. Darolutamide [39] AHMAD F，CHERUKURI M K，CHOYKE P L. Meta‐
plus androgen-deprivation therapy and docetaxel in meta‐ bolic reprogramming in prostate cancer[J]. Br J Cancer，
static hormone-sensitive prostate cancer by disease vo- 2021，125（9）：1185-1196.
lume and risk subgroups in the phase Ⅲ ARASENS trial [40] MARKOWSKI M C，TUTRONE R，PIECZONKA C，
[J]. J Clin Oncol，2023，41（20）：3595-3607. et al. A phase Ⅰb/Ⅱ study of sabizabulin，a novel oral cy‐
[29] UEMURA M，KIKUKAWA H，HASHIMOTO Y，et al. toskeleton disruptor，in men with metastatic castration-
Darolutamide in Japanese patients with metastatic resistant prostate cancer with progression on an androgen
hormone-sensitive prostate cancer：phase 3 ARASENS receptor-targeting agent[J]. Clin Cancer Res，2022，28
subgroup analysis[J]. Cancer Med，2024，13（21）：e70029. （13）：2789-2795.
[30] WANG C，ZHANG Y，GAO W Q. The evolving role of [41] CHEN H，DENG S S，WANG Y X，et al. Structure-
immune cells in prostate cancer[J]. Cancer Lett，2022， activity relationship study of novel 6-aryl-2-benzoyl-
525：9-21. pyridines as tubulin polymerization inhibitors with potent
[31] MA Z H，ZHANG W W，DONG B J，et al. Docetaxel re‐ antiproliferative properties[J]. J Med Chem，2020，63（2）：
models prostate cancer immune microenvironment and en‐ 827-846.
hances checkpoint inhibitor-based immunotherapy[J]. [42] LAI J N，TSENG Y J，CHEN M H，et al. Clinical perspec‐
Theranostics，2022，12（11）：4965-4979. tive of FDA approved drugs with P-glycoprotein inhibi‐
[32] CEVATEMRE B，BULUT I，DEDEOGLU B，et al. Ex‐ tion activities for potential cancer therapeutics[J]. Front
ploiting epigenetic targets to overcome taxane resistance Oncol，2020，10：561936.
in prostate cancer[J]. Cell Death Dis，2024，15（2）：132. [43] SEO H K，LEE S J，KWON W A，et al. Docetaxel-
[33] LIMA T S，SOUZA L O，IGLESIAS-GATO D，et al. Itra‐ resistant prostate cancer cells become sensitive to gem‐
conazole reverts ABCB1-mediated docetaxel resistance in citabine due to the upregulation of ABCB1[J]. Prostate，
prostate cancer[J]. Front Pharmacol，2022，13：869461. 2020，80（6）：453-462.
[34] SEKINO Y，HAN X R，KAWAGUCHI T，et al. TUBB3 [44] SOUCHEK J J，LALIWALA A，HOUSER L，et al. Fatty
reverses resistance to docetaxel and cabazitaxel in prostate acid synthase inhibitors enhance microtubule-stabilizing
cancer[J]. Int J Mol Sci，2019，20（16）：3936. and microtubule-destabilizing drugs in taxane-resistant
[35] CHENG B S，LI L F，LUO T L，et al. Single-cell deconvo‐ prostate cancer cells[J]. ACS Pharmacol Transl Sci，2023，
lution algorithms analysis unveils autocrine IL11-media- 6（12）：1859-1869.
ted resistance to docetaxel in prostate cancer via activation [45] YEDLA P，BABALGHITH A O，ANDRA V V，et al.
of the JAK1/STAT4 pathway[J]. J Exp Clin Cancer Res， PROTACs in the management of prostate cancer[J]. Mo-
2024，43（1）：67. lecules，2023，28（9）：3698.
[36] SUN X C，ZHANG Y，XIN S Y，et al. NOTCH3 promotes [46] CHEN P，WANG S B，CAO C Y，et al. α-naphthoflavone-
docetaxel resistance of prostate cancer cells through regu‐ derived cytochrome P450 （CYP）1B1 degraders specific
lating TUBB3 and MAPK signaling pathway[J]. Cancer for sensitizing CYP1B1-mediated drug resistance to pros‐
Sci，2024，115（2）：412-426. tate cancer DU145：structure activity relationship[J].
[37] ZHANG Z L，WANG W X，KONG P P，et al. New in‐ Bioorg Chem，2021，116：105295.
sights into lipid metabolism and prostate cancer：review （收稿日期：2025-02-10 修回日期：2025-05-29）
[J]. Int J Oncol，2023，62（6）：74. （编辑：唐晓莲）

· 1688 · China Pharmacy 2025 Vol. 36 No. 13 中国药房 2025年第36卷第13期